Full Press Release Details
A Statement from Biogen on Access to LEQEMBI™.
BIIB
A Statement from Biogen on Access to LEQEMBI™
Key Takeaway: A Statement from Biogen on Access to LEQEMBI™
Price reaction · baseline $256.56 (2023-03-10 close) · 2 other BIIB headline(s) in the window, move may be shared
day 0 close · peak
+0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis